Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769540 | 0.96 | KDM4E (0.51) | USP2KDM4EPOLBL3MBTL1MAPT | |
| SCHEMBL21769242 | 0.93 | USP2 (0.52) | USP2KDM4EPOLBL3MBTL1EPHX2 | |
| SCHEMBL21769399 | 0.91 | USP2 (0.57) | USP2KDM4EPOLBL3MBTL1ABCB1 | |
| SCHEMBL21769472 | 0.90 | NPSR1 (0.48) | USP2KDM4EPOLBMAPTMAPK1 | |
| SCHEMBL21769478 | 0.89 | KDM4E (0.51) | USP2KDM4EPOLBL3MBTL1MAPT | |
| SCHEMBL21750490 | 0.86 | KDM4E (0.56) | USP2KDM4EPOLBL3MBTL1ABCB1 | |
| SCHEMBL21769534 | 0.83 | NPSR1 (0.48) | USP2KDM4EPOLBMAPTMAPK1 | |
| SCHEMBL21769539 | 0.83 | KDM4E (0.52) | KDM4EPOLBMAPTMAPK1NPSR1 | |
| SCHEMBL21769525 | 0.83 | USP2 (0.50) | USP2KDM4EPOLBL3MBTL1ABCB1 | |
| SCHEMBL21769401 | 0.81 | ALDH1A1 (0.53) | USP2KDM4EPOLBL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | USP2 4760/4885KDM4E 3638/4885POLB 2907/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | USP2 4760/4885KDM4E 3638/4885POLB 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.